Effect of Hysteroscopic Metroplasty on Reproductive Outcome in Patients with RIF
Launched by SHANGHAI FIRST MATERNITY AND INFANT HOSPITAL · Feb 21, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • At least twice previous implantation failures
- • Willing to receive further embryo transfer
- Exclusion Criteria:
- • Sturctural intrauterine lesions
- • Severe adenomyosis
- • Premature ovarian failure
- • BMI \> 35 kg/m\^2
- • Severe systemic disease or maligant tumor
About Shanghai First Maternity And Infant Hospital
Shanghai First Maternity and Infant Hospital is a leading healthcare institution dedicated to providing comprehensive maternal and pediatric care. With a strong emphasis on clinical research and innovation, the hospital is committed to advancing medical knowledge and improving patient outcomes through rigorous clinical trials. Leveraging its expert team of healthcare professionals and state-of-the-art facilities, the hospital aims to address critical health challenges faced by mothers and infants, thereby contributing to the enhancement of healthcare standards both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported